Bavituximab: Phase II data

Data from 38 patients with advanced HCC in the Phase II portion of an open-label, U.S. Phase I/II trial showed that once-weekly 3 mg/kg IV bavituximab plus twice-daily 400 mg Nexavar sorafenib led to...